RU2002109595A - Амфифильные пролекарства - Google Patents

Амфифильные пролекарства Download PDF

Info

Publication number
RU2002109595A
RU2002109595A RU2002109595/14A RU2002109595A RU2002109595A RU 2002109595 A RU2002109595 A RU 2002109595A RU 2002109595/14 A RU2002109595/14 A RU 2002109595/14A RU 2002109595 A RU2002109595 A RU 2002109595A RU 2002109595 A RU2002109595 A RU 2002109595A
Authority
RU
Russia
Prior art keywords
prodrug
therapeutic compound
etoposide
oligomers
peg
Prior art date
Application number
RU2002109595/14A
Other languages
English (en)
Russian (ru)
Inventor
Нночири Н. ЭКВЮРАЙБ (US)
Нночири Н. ЭКВЮРАЙБ
Тать на А. ДЬЯКОНОВ (US)
Татьяна А. ДЬЯКОНОВ
Кристофер Х. ПРАЙС (US)
Кристофер Х. ПРАЙС
Original Assignee
Нобекс Корпорейшн (Us)
Нобекс Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нобекс Корпорейшн (Us), Нобекс Корпорейшн filed Critical Нобекс Корпорейшн (Us)
Publication of RU2002109595A publication Critical patent/RU2002109595A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
RU2002109595/14A 1999-09-13 2000-09-07 Амфифильные пролекарства RU2002109595A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15364999P 1999-09-13 1999-09-13
US60/153,649 1999-09-13
US09/474,915 US6713454B1 (en) 1999-09-13 1999-12-31 Prodrugs of etoposide and etoposide analogs
US09/474,915 1999-12-31

Publications (1)

Publication Number Publication Date
RU2002109595A true RU2002109595A (ru) 2003-11-27

Family

ID=26850733

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002109595/14A RU2002109595A (ru) 1999-09-13 2000-09-07 Амфифильные пролекарства

Country Status (17)

Country Link
US (3) US6713454B1 (US07119074-20061010-C00003.png)
EP (1) EP1212099A2 (US07119074-20061010-C00003.png)
JP (1) JP2003509385A (US07119074-20061010-C00003.png)
KR (1) KR20020059398A (US07119074-20061010-C00003.png)
CN (1) CN1390143A (US07119074-20061010-C00003.png)
AU (1) AU7575600A (US07119074-20061010-C00003.png)
BR (1) BR0013948A (US07119074-20061010-C00003.png)
CA (1) CA2384645A1 (US07119074-20061010-C00003.png)
CZ (1) CZ2002928A3 (US07119074-20061010-C00003.png)
HU (1) HUP0204110A3 (US07119074-20061010-C00003.png)
IL (1) IL148558A0 (US07119074-20061010-C00003.png)
MX (1) MXPA02002712A (US07119074-20061010-C00003.png)
NO (1) NO20021213L (US07119074-20061010-C00003.png)
NZ (1) NZ517681A (US07119074-20061010-C00003.png)
PL (1) PL354261A1 (US07119074-20061010-C00003.png)
RU (1) RU2002109595A (US07119074-20061010-C00003.png)
WO (1) WO2001019406A2 (US07119074-20061010-C00003.png)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US6380405B1 (en) * 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
US6541508B2 (en) 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
US6713454B1 (en) * 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
DE60032255T2 (de) * 1999-10-04 2007-06-28 Nektar Therapeutics Al, Corp., Huntsville Polymer-stabilisierte neuropeptide
WO2001078784A1 (en) * 2000-04-15 2001-10-25 Kolon Industries, Inc. Aqueous-prodrug compound comprising moiety of paclitxel or derivatives thereof, method of preparing same and pharmaceutical composition comprising same
DE60205470T2 (de) * 2002-03-28 2006-05-24 Council Of Scientific And Industrial Research Analoge von 4-beta-1''-[(2''-(substitutierte-benzoyl)anilin]-podophyllotoxin zur verwendung als antikrebs-agentia 4-beta-1"-∫2"-(substituted benzoyl) anilino∫ podophyllotoxin analogues useful as anticancer agents
WO2004035037A2 (en) * 2002-10-21 2004-04-29 Ramot At Tel Aviv University Ltd. Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
EP1569683B1 (en) * 2002-11-26 2010-03-03 Biocon Limited Modified natriuretic compounds, conjugates, and uses thereof
SI1583562T1 (sl) * 2003-01-06 2011-10-28 Angiochem Inc AngioPep-1, sorodne spojine in njihove uporabe
US7140522B2 (en) * 2003-06-26 2006-11-28 Spencer Forrest, Inc. Applicator for hair building solids
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
CN102895666B (zh) * 2003-12-16 2015-08-19 尼克塔治疗公司 化学改性的小分子
NZ548195A (en) * 2004-01-14 2011-01-28 Gilead Sciences Inc Lipid-based dispersions useful for drug delivery
US8329958B2 (en) 2004-07-02 2012-12-11 Biocon Limited Combinatorial synthesis of PEG oligomer libraries
CN101023119B (zh) * 2004-09-22 2010-05-05 日本化药株式会社 新型嵌段共聚物，胶束制剂以及含胶束制剂为活性组分的抗癌剂
WO2006076471A2 (en) * 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
ES2383901T5 (es) * 2005-02-18 2015-02-25 Angiochem Inc. Polipéptidos de aprotinina para transportar un compuesto a través de la barrera sangre-cerebro
CN101262890B (zh) 2005-07-15 2015-08-26 安吉奥化学公司 抑肽酶多肽作为载体在药物缀合物中的用途
JP5173199B2 (ja) * 2006-01-16 2013-03-27 株式会社アイ・ティー・オー 創傷治癒用高分子組成物
KR20080106254A (ko) 2006-03-28 2008-12-04 니폰 가야꾸 가부시끼가이샤 탁산류의 고분자 결합체
WO2007135910A1 (ja) * 2006-05-18 2007-11-29 Nippon Kayaku Kabushiki Kaisha ポドフィロトキシン類の高分子結合体
CA2664852A1 (en) * 2006-10-03 2008-04-10 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of resorcinol derivatives
WO2008056596A1 (en) 2006-11-06 2008-05-15 Nippon Kayaku Kabushiki Kaisha Polymeric derivative of nucleic acid metabolic antagonist
EP2090607B1 (en) 2006-11-08 2015-05-20 Nippon Kayaku Kabushiki Kaisha Polymeric derivative of nucleic acid metabolic antagonist
US9365634B2 (en) * 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
CN101868443A (zh) 2007-09-20 2010-10-20 特拉维夫大学拉莫特有限公司 N-苯基邻氨基苯甲酸衍生物及其用途
WO2009041570A1 (ja) * 2007-09-28 2009-04-02 Nippon Kayaku Kabushiki Kaisha ステロイド類の高分子結合体
CN101977631A (zh) * 2008-03-18 2011-02-16 日本化药株式会社 生理活性物质的高分子量偶联物
RU2518240C2 (ru) * 2008-04-18 2014-06-10 Ангиочем Инк. Композиция, на основе гидрофобных агентов и способ ее получения(варианты)
WO2009136572A1 (ja) 2008-05-08 2009-11-12 日本化薬株式会社 葉酸若しくは葉酸誘導体の高分子結合体
US20100075926A1 (en) * 2008-07-23 2010-03-25 Li-Huei Tsai Activation of histone deacetylase 1 (hdac1) protects against dna damage and increases neuronal survival
BRPI0920121A2 (pt) 2008-10-15 2019-09-24 Angiochem Inc conjugados de etoposida e doxorubicina para liberação de fármaco
JP2012505637A (ja) 2008-10-15 2012-03-08 アンジオケム，インコーポレーテッド Ｇｌｐ−１アゴニストのコンジュゲート及びその使用
JP5759379B2 (ja) * 2008-12-05 2015-08-05 アンジオケム インコーポレーテッド ニューロテンシンまたはニューロテンシンアナログおよびその使用
EP2373789A4 (en) 2008-12-17 2012-08-29 Angiochem Inc MEMBRANTYP-1 MATRIX METALLOPROTEINASE INHIBITORS AND THEIR USE
WO2010121379A1 (en) 2009-04-20 2010-10-28 Angiochem Inc Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
US8808749B2 (en) 2009-05-15 2014-08-19 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of bioactive substance having hydroxy group
AU2010268726A1 (en) 2009-07-02 2012-01-19 Angiochem Inc. Multimeric peptide conjugates and uses thereof
CA2779497A1 (en) 2009-10-30 2011-05-05 Massachusetts Institute Of Technology The use of ci-994 and dinaline for the treatment of memory/cognition and anxiety disorders
US9561285B2 (en) * 2010-01-22 2017-02-07 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
WO2011141891A1 (en) 2010-05-12 2011-11-17 Debio Recherche Pharmaceutique S.A. Use of cycloundecadepsipeptide compounds
EP2624869A4 (en) * 2010-10-08 2015-11-04 Univ Virginia Commonwealth PRODRUGS USING A CONTAINER CONTROLLED ABSORPTION MECHANISM
EP2641605B1 (en) 2010-11-17 2018-03-07 Nippon Kayaku Kabushiki Kaisha Polymer derivative of cytidine metabolism antagonist
WO2012149540A1 (en) 2011-04-28 2012-11-01 The Broad Institute Inc Inhibitors of histone deacetylase
TR201901856T4 (tr) 2011-07-22 2019-03-21 Massachusetts Inst Technology Sınıf I histon deasetilazların (HDAC'ler) aktivatörleri ve kullanımları.
RU2623426C2 (ru) 2011-09-11 2017-06-26 Ниппон Каяку Кабусики Кайся Способ получения блок-сополимера
US8993614B2 (en) 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
EP2852439A1 (en) 2012-05-23 2015-04-01 Stemergie Biotechnology SA Inhibitors of the activity of complex (iii) of the mitochondrial electron transport chain and use thereof
WO2014100438A1 (en) 2012-12-20 2014-06-26 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
CA2989400A1 (en) 2015-06-15 2016-12-22 Angiochem Inc. Ang1005 for the treatment of leptomeningeal carcinomatosis
WO2016205631A1 (en) 2015-06-17 2016-12-22 Massachusetts Institute Of Technology Serotonin 2c receptor antagonists to prevent and treat stress-related trauma disorders
JP2020533992A (ja) 2017-09-18 2020-11-26 マサチューセッツ インスティテュート オブ テクノロジー サイクリン依存性キナーゼ５（ｃｄｋ５）阻害性ペプチド
CN112266409B (zh) * 2020-10-28 2022-05-13 南开大学 依托泊苷自组装纳米纤维多肽、制备方法及应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US611107A (en) * 1898-09-20 Method of forming tobacco into wrappers
ATE28864T1 (de) 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
US4567253A (en) 1984-02-03 1986-01-28 Tony Durst 2-Substituted derivatives of podophyllotoxin and etoposide
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
DE3935016A1 (de) 1989-10-20 1991-04-25 Behringwerke Ag Glycosyl-etoposid-prodrugs, verfahren zu ihrer herstellung und ihre anwendung in kombination mit funktionalisiertem tumorspezifischen enzym-konjugaten
US5219564A (en) 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
US5407683A (en) 1990-06-01 1995-04-18 Research Corporation Technologies, Inc. Pharmaceutical solutions and emulsions containing taxol
AU4406793A (en) 1992-06-04 1993-12-30 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
IT1256345B (it) 1992-08-20 1995-12-01 Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione
US5614549A (en) * 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
WO1994005282A1 (en) 1992-09-04 1994-03-17 The Scripps Research Institute Water soluble taxol derivatives
US5817321A (en) 1992-10-08 1998-10-06 Supratek Pharma, Inc. Biological agent compositions
IT1256450B (it) 1992-11-26 1995-12-05 Soldato Piero Del Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione
US5298643A (en) 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
US5349001A (en) 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
WO1994020453A1 (en) 1993-03-09 1994-09-15 Enzon, Inc. Taxol polyalkylene oxide conjugates of taxol and taxol intermediates
US5547981A (en) 1993-03-09 1996-08-20 Enzon, Inc. Taxol-7-carbazates
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
JPH0782291A (ja) 1993-09-13 1995-03-28 Microbial Chem Res Found 水溶性アンスラサイクリン誘導体
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5824701A (en) 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
US5965566A (en) 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5622986A (en) 1993-10-20 1997-04-22 Enzon, Inc. 2'-and/or 7-substituted taxanes
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5618528A (en) 1994-02-28 1997-04-08 Sterling Winthrop Inc. Biologically compatible linear block copolymers of polyalkylene oxide and peptide units
US5730990A (en) 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5547027A (en) * 1994-07-14 1996-08-20 Dowell, A Division Of Schlumberger Technology Corporation Low temperature, low rheology synthetic cement
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5756593A (en) 1995-05-15 1998-05-26 Enzon, Inc. Method of preparing polyalkyene oxide carboxylic acids
JP3737518B2 (ja) 1996-03-12 2006-01-18 ピージー−ティーエックスエル カンパニー， エル．ピー． 水溶性パクリタキセルプロドラッグ
WO1997038727A1 (fr) 1996-04-15 1997-10-23 Asahi Kasei Kogyo Kabushiki Kaisha Composite medicamenteux
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
DE19636889A1 (de) * 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
CA2265476A1 (en) 1996-09-12 1998-03-19 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
IL133585A0 (en) 1997-06-20 2001-04-30 Baker Norton Pharma Soluble prodrugs of paclitaxel
US6011042A (en) 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
US6111107A (en) 1997-11-20 2000-08-29 Enzon, Inc. High yield method for stereoselective acylation of tertiary alcohols
WO1999030727A1 (en) 1997-12-17 1999-06-24 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US5965119A (en) 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
JP2002512640A (ja) 1998-03-23 2002-04-23 コンジュケム，インコーポレーテッド 持続性治療薬の局所送達
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
EP1176985A2 (en) 1999-04-28 2002-02-06 Vectramed, Inc. Enzymatically activated polymeric drug conjugates
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US6593292B1 (en) 1999-08-24 2003-07-15 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6380405B1 (en) 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
US6541508B2 (en) 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs

Also Published As

Publication number Publication date
US20040253206A1 (en) 2004-12-16
CA2384645A1 (en) 2001-03-22
MXPA02002712A (es) 2003-10-14
NO20021213L (no) 2002-05-13
NO20021213D0 (no) 2002-03-12
AU7575600A (en) 2001-04-17
BR0013948A (pt) 2002-05-14
CN1390143A (zh) 2003-01-08
NZ517681A (en) 2004-01-30
EP1212099A2 (en) 2002-06-12
HUP0204110A2 (hu) 2003-04-28
HUP0204110A3 (en) 2003-08-28
CZ2002928A3 (cs) 2002-09-11
KR20020059398A (ko) 2002-07-12
US20040180840A1 (en) 2004-09-16
WO2001019406A2 (en) 2001-03-22
IL148558A0 (en) 2002-09-12
PL354261A1 (en) 2003-12-29
US7119074B2 (en) 2006-10-10
JP2003509385A (ja) 2003-03-11
US6713454B1 (en) 2004-03-30
WO2001019406A3 (en) 2002-01-17

Similar Documents

Publication Publication Date Title
RU2002109595A (ru) Амфифильные пролекарства
CN101605539B (zh) 用7-乙基-10-羟基喜树碱的多臂聚合缀合物治疗抵抗性或顽固性癌症
RU2587013C2 (ru) Комбинированная химиотерапия
US6403563B1 (en) Antitumor composition containing a synergistic combination of an anthracycline derivative with a camptothecin derivate
JP2001520189A5 (US07119074-20061010-C00003.png)
WO1990002550A1 (en) Treatment of damaged bone marrow and dosage units therefor
JP2003501488A5 (US07119074-20061010-C00003.png)
UA70942C2 (uk) Застосування n-заміщеного індоліл-3-гліоксиламіду як протипухлинного засобу, спосіб лікування пухлинних захворювань та лікарська композиція для лікування пухлинних захворювань
KR20030048127A (ko) 효과적인 항종양 치료
CN1181014A (zh) 抑制病毒和癌生长的含n-膦酰甘氨酸衍生物的药物组合物
RU95121694A (ru) Применение аналогов ацилфульвена и фармацевтическая композиция на их основе
JP2005509650A (ja) 癌治療における抗腫瘍化合物の改良した使用
Zou et al. Effectiveness of water soluble poly (L-glutamic acid)-camptothecin conjugate against resistant human lung cancer xenografted in nude mice
EP0952854A2 (en) Composition comprising non-radioactive metal ion complexes with phosphonate compounds for the palliation of pain associated with diseases of the bone and bone joints
EP1345604B1 (en) Use of a alpha-halogen-acryloyl distamycin derivate for the preparation of a medicament for the treatment of cancer
IT1262921B (it) Agenti antitumorali analoghi di oligopeptidi pirrol-amidinici retroversi processi di preparazione e prodotti farmaceutici che li contengono
US6596320B1 (en) Method for treating cancer having greater efficacy and reduced adverse effects
Plonowski et al. Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238
Butler et al. Optimal therapy for small noncleaved cell lymphoma
US20040110838A1 (en) Method of reducing toxicity of anticancer agents
US6593303B1 (en) Anti-tumor synergetic composition
AU2002251763A1 (en) Method for treating cancer
WO2002056755A2 (en) Method for treating cancer
RU2002109594A (ru) Таксановые пролекарства
Bodey et al. Clinical evaluation of asaley

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20050301